A perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread;Ein perioperatives screening auf metastasen ist bei patientinnen mit einem primär operablem mammakarzinom und fehlender klinischer symptomatik einer metastasierung nicht indiziert

Zentralblatt fur Gynakologie

Volumn 126, Issue 4, 2004, Pages 275-279

  Gerber, Bernd ^a,c   Seltz, E ^b   Muller H ^b   Krause, A ^a   Reimer, T ^b   Janni, W ^a   Kundt, G ^b   Friese, K ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Breast cancer; Costs; Metastatic disease; Staging; Treatment

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BONE SCINTISCANNING; BREAST CANCER; CANCER CYTODIAGNOSIS; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; COST CONTROL; DIAGNOSTIC ERROR; ECHOGRAPHY; FEMALE; HEALTH CARE COST; HUMAN; INTRAOPERATIVE PERIOD; LIVER; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PROGNOSIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; TUMOR VOLUME;

ADULT; AGE FACTORS; BREAST NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT SELECTION; PREOPERATIVE CARE; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 4444380379     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-822753     Document Type: Article

References (33)

1. Barry MC, Thornton F, Murphy M, Younis F, Watson RG. The value of metastatic screening in early primary breast cancer. Ir J Med Sci 1999; 168: 248-250
2. th century: most up-to-date estimates from the nationwide Finnish cancer registry. Br J Cancer 2001; 85: 367-371
3. Bruneton JN, Balu-Maestro C, Raffaelli C, Mourou MY, Cambon P, Granon C. Indications for hepatic ultrasonography in breast cancer staging and follow-up. Breast Cancer Res Treat 1996; 37: 115-121
4. Chen EA, Carlson GA, Coughlin BF, Reed WPJ, Garb JL, Frank JL. Routine chest roentgenography is unnecessary in the work-up of stage I and II breast cancer. J Clin Oncol 2000; 18: 3503-3506
5. Cooke AL. Baseline staging tests for breast cancer. CMAJ 2002; 166: 419
6. Curigliano G, Ferretti G, Colleoni M, Marrocco E, Peruzzotti G, De Cicco C, Paganelli G, Goldhirsch A. Bone scan had no role in the staging of 765 consecutive operable T(1-2)N(0-1) breast cancer patients without skeletal symptoms. Ann Oncol 2001; 12: 724-725
7. Dillman RO, Chico S. Radiologic tests after a new diagnosis of breast cancer. Eff Clin Pract 2000; 3: 1-6
8. Donnelly J, Mack P, Donaldson LA. Follow-up of breast cancer: time for a new approach? Int J Clin Pract 2001; 55: 431-433
9. ESMO. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol 2001; 12: 1047-1048
10. Gerber B, Seitz E, Krause A, Müller H, Reimer T, Küchenmeister I, Kundt G, Friese K. A perioperative staging for distant metastases in primary operable breast cancer patients is indicated only in advanced cases. Breast Cancer Res Treat 2003; 82: 29-37
11. GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 1994; 271: 1587-1592
12. Goldhirsch A, Glick JH, Gelber RD, Coates A, Senn HJ. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 2003; 21: 3357-3365
13. Hadley D, Fowble B, Torosian MH. Evidence for selective use of bone scans in early stage breast cancer. Oncol Rep 1998; 5: 991-993
14. Hoffken K. The European experience. J Clin Oncol 2001; 19: 112S-117S
15. Myers RE, Johnston M, Pritchard K, Levine M, Oliver T. Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 2001; 164: 1439-1444
16. Nabholtz J, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C, Weaver C, Walley M. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study. Proc ASCO 2002; 21: 36a
17. NIH. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001; 5-15
18. Niu Y, Fu X, Lv A, Fan Y, Wang Y. Potential markers predicting distant metastasis in axillary node-negative breast carcinoma. Int J Cancer 2002; 98: 754-760
19. Norum J, Andreassen T. Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective? Anticancer Res 2000; 20: 2193-2196
20. Palli D, Russo A, Saieva C, Ciatto S, Rosselli DT, Distante V, Pacini P. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year-update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA 1999; 281: 1586
21. Ravaioli A, Pasini G, Polselli A, Papi M, Tassinari D, Arcangeli V, Milandri C, Amadori D, Bravi M, Rossi D, Fattori PP, Pasquini E, Panzini I. Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat 2002: 72: 53-60
22. Ravaioli A, Tassinari D, Panzini I, Milandri C, Amadori D. Staging of breast cancer: it is time to break with tradition and initiate the evidence-based-medicine age. J Clin Oncol 2001; 19: 1234
23. Rojas MP, Telaro E, Russo A, Fossati R, Confalonieri C, Liberati A. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2000: CD001768
24. Rosselli DT, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994; 271: 1593-1597
25. Sakorafas GH, Tsiotou AG, Pavlakis G. Follow-up after primary treatment for breast cancer. Acta Oncol 2000; 39: 935-940
26. Samant R, Ganguly P. Staging investigations in patients with breast cancer: the role of bone scans and liver imaging. Arch Surg 1999; 134: 551-553
27. Sant M. Differences in stage and therapy for breast cancer across Europe. Int J Cancer 2001; 93: 894-901
28. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636
29. Sittek H, de Waal C, Eiermann W, Engel J, Gauwerky JF, Hellemann HP. Screening und Diagnsotik. In: Mannual Mammakarzinom (Hrsg). 9.Aufl.Tumorzentrum München 2003; 28-40
30. Tassinari D, Sartori S, Ravaioli A. Staging of breast cancer. Is the evidence so evident? Ann Oncol 2001; 12: 1653
31. Vacek PM, Geller BM, Weaver DL, Foster RSJ. Increased mammography use and its impact on earlier breast cancer detection in Vermont, 1975-1999. Cancer 2002; 94: 2160-2168
32. Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000; 36: 724-735
33. Wingo PA, Ries LA, Giovino GA, Miller DS, Rosenberg HM, Shopland DR, Thun MJ, Edwards BK. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91: 675-690